Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injuryAnnayya R. Aroor(Harry S. Truman Memorial Veterans' Hospital), Vincent G. DeMarco(University of Missouri)Cardiovascular DiabetologyJuly 30, 201810.1186/s12933-018-0750-8Cited by 177SaveCiteExport RISWatch citationsRelated PapersDipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice|Cardiovascular Diabetology|2017|70